Target intelligence / Profile preview

Coli surface antigen (CS) (CS)

Target
CS
Molecular classification
Adhesin, Bacterial surface protein, Fimbriae, Pilus
01

Overview

Coli surface antigens (CSs) are a diverse group of proteinaceous surface structures, primarily fimbriae or pili, expressed by Enterotoxigenic Escherichia coli (ETEC) (Qadri et al., 2005). They function as essential adhesins that mediate the attachment of the bacteria to specific receptors on the human intestinal mucosa, which is a critical first step in colonization and subsequent delivery of enterotoxins (Fleckenstein et al., 2010; Zhang et al., 2023). There are over 25 identified CS variants, such as CS1 through CS6, which are often plasmid-encoded and vary in prevalence across different geographic regions (Vidal et al., 2019; Frontiers, 2018). Because colonization is a prerequisite for ETEC-induced diarrhea, these antigens are primary targets for vaccine development, including whole-cell killed vaccines like ETVAX and multivalent subunit vaccines like MecVax (Svennerholm, 2011; MDPI, 2023). Blocking the interaction between CSs and host receptors through vaccine-induced antibodies prevents the establishment of infection and the resulting secretory diarrhea (NIH, 2023; ASM, 2023). This approach is particularly important for protecting children in endemic areas and travelers to high-risk regions, although the high degree of antigenic diversity remains a significant challenge for achieving broad vaccine coverage (Frontiers, 2018; ASM, 2023).

Other names
Colonization factor antigenCFAColonization factorCFETEC adhesinFimbriaePili
02

Mechanism of action

Induction of mucosal and systemic antibodies (IgA and IgG) that bind to the surface antigens, preventing bacterial attachment to intestinal epithelial cells and subsequent colonization.

03

Biological functions

Bacterial adhesionColonizationPathogenesis
04

Disease associations

InfectionDiarrhea
05

Safety considerations

Antigenic variation and diversityStrain replacementLimited cross-protection between different CS typesGeographic variability of expressed antigens
06

Interacting drugs

ETVAX

3 more in the full profile.

07

Biomarkers

Anti-CS IgA antibody levelsAnti-CS IgG antibody levelsAntibody in Lymphocyte Supernatant (ALS)Fecal IgA

Beyond the preview

Go deeper on Coli surface antigen (CS) (CS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coli surface antigen (CS) (CS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call